Pfizer Inc. (0Q1N)
LSE
28.21
+0.43 (+1.53%)
Closed
Oct 9, 2026
Day's Range
27.6028.25
52 wk Range
21.8337.43
Financial Statements - 0Q1N - Pfizer Inc.
Revenue
62.57B▼ 1.6%
Net Income
7.81B▼ 3.1%Net Margin 12.5%
EBITDA
25.74B▲ 13.9%
Free Cash Flow
9.07B▼ 7.7%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 62.57B | 63.62B | 58.49B | 100.33B | 81.28B | 41.65B |
| Cost of Goods | 16.06B | 17.85B | 24.95B | 34.34B | 30.82B | 8.48B |
| Gross Profit | 46.51B | 45.77B | 33.54B | 65.98B | 50.46B | 33.16B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 17.40B | 14.83B | 3.35B | 37.27B | 23.70B | 8.82B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -7.81B | -4.26B | -1.71B | -1.55B | 1.76B | -415M |
| Pre Tax Income | 7.52B | 8.02B | 1.05B | 34.72B | 24.31B | 7.03B |
| Income Tax | -266M | -28M | -1.11B | 3.32B | 1.85B | 370M |
| Net Income | 7.81B | 8.06B | 2.15B | 31.40B | 22.02B | 9.19B |
| EPS Basic | 1.37 | 1.42 | 0.38 | 5.59 | 3.92 | 1.73 |
| EPS Diluted | 1.36 | 1.41 | 0.37 | 5.47 | 3.85 | 1.71 |
| Basic Shares Outstanding | 5.68B | 5.66B | 5.64B | 5.60B | 5.60B | 5.55B |
| Diluted Shares Outstanding | 5.68B | 5.66B | 5.64B | 5.60B | 5.60B | 5.55B |
| Ebit | 10.19B | 11.11B | 3.26B | 35.96B | 25.60B | 8.48B |
| Ebitda | 25.74B | 22.60B | 14.44B | 45.09B | 33.59B | 14.92B |
| Net Income Continuous Operations | 7.78B | 8.05B | 2.17B | 31.40B | 22.45B | 7.02B |
| Minority Interests | -41M | -31M | -39M | -35M | -45M | -36M |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
